Centessa Pharmaceuticals plc — Director's Dealing 2021

May 28, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-05-27

Reporting Person: Hedley Mary Lynne (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Share Option (right to buy)	$5.84	2031-02-19	Ordinary Shares (208474)		Direct

Footnotes

F1: 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

F2: Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.

F3: Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.